Frankfurt - Delayed Quote ? EUR KalVista Pharmaceuticals, Inc. (4XC1.F) Follow Compare 10.90 -0.40 (-3.54%) At close: October 18 at 8:16 AM GMT+2 Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 4XC1.F 1D 5D 9.55% 1M 15.34% 3M -20.44% 6M 0.00% YTD 0.00% 1Y 26.01% 2Y 137.11% 5Y 6.86% All 23.58% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: 4XC1.F View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) Business Wire ? yesterday KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum Business Wire ? 15 days ago KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire ? 17 days ago High Growth Tech Stocks To Watch In The United States Simply Wall St. ? 17 days ago KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema Business Wire ? 19 days ago KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF) Business Wire ? 23 days ago KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference Business Wire ? last month KalVista Appoints Brian Piekos as Chief Financial Officer Business Wire ? last month KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 Business Wire ? last month KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update Business Wire ? last month KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema Business Wire ? last month View More
